| Nov 21 |
Sage ends dalzanemdor development following Phase II trial failure
|
| Nov 21 |
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
|
| Nov 21 |
Sage raised to sector perform by RBC in wake of drug failure
|
| Nov 20 |
After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
|
| Nov 20 |
Sage slips as Huntington’s Disease therapy fails in mid-stage trial
|
| Nov 20 |
Sage’s string of research failures continues
|
| Nov 20 |
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
|
| Nov 19 |
CNS Drug Development: Same As It Ever Was
|
| Oct 31 |
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
|
| Oct 30 |
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|
